Flurbiprofen
Flurbiprofen|
|
| Systematic (IUPAC) name |
|---|
|
(RS)-2-(2-fluorobiphenyl-4-yl)propanoic acid |
| Clinical data |
|---|
| Trade names |
Ansaid, Ocufen, Strepfen |
|---|
| AHFS/Drugs.com |
monograph |
|---|
| MedlinePlus |
a687005 |
|---|
Pregnancy category |
|
|---|
Routes of administration |
Oral |
|---|
| Legal status |
|---|
| Legal status |
|
|---|
| Pharmacokinetic data |
|---|
| Protein binding |
> 99% |
|---|
| Metabolism |
Hepatic (CYP2C9) |
|---|
| Biological half-life |
4.7-5.7 hours |
|---|
| Excretion |
Renal |
|---|
| Identifiers |
|---|
| CAS Number |
5104-49-4 Y |
|---|
| ATC code |
M01AE09 (WHO) , M02AA19 (WHO), R02AX01 (WHO), S01BC04 (WHO) |
|---|
| PubChem |
CID 3394 |
|---|
| IUPHAR/BPS |
4194 |
|---|
| DrugBank |
DB00712 Y |
|---|
| ChemSpider |
3277 Y |
|---|
| UNII |
5GRO578KLP Y |
|---|
| KEGG |
D00330 Y |
|---|
| ChEBI |
CHEBI:5130 Y |
|---|
| ChEMBL |
CHEMBL563 Y |
|---|
| Synonyms |
(±)-2-fluoro-α-methyl-(1,1'-biphenyl)-4-acetic acid |
|---|
| PDB ligand ID |
FLP (PDBe, RCSB PDB) |
|---|
| Chemical data |
|---|
| Formula |
C15H13FO2 |
|---|
| Molar mass |
244.261 g/mol |
|---|
| Chirality |
Racemic mixture |
|---|
Fc2cc(ccc2c1ccccc1)C(C(=O)O)C
|
InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18) YKey:SYTBZMRGLBWNTM-UHFFFAOYSA-N Y
|
| Physical data |
|---|
| Melting point |
117 °C (243 °F) |
|---|
| (verify) |
|---|
Flurbiprofen is a member of the phenylalkanoic acid derivative family of non-steroidal anti-inflammatory drugs (NSAIDs). It is primarily indicated as a pre-operative anti-miotic (in an ophthalmic solution) as well as orally for arthritis or dental pain.[1] It is generic and is marketed under brand names worldwide, including "Ansaid" and "Froben".[2]
It was derived from propionic acid by the research arm of Boots UK during the 1960s, a period which also included the discovery of ibuprofen, indometacin, diclofenac, naproxen, ketoprofen, and sulindac.[3][4][5]:34
Side effects are analogous to those of ibuprofen. As of 2015 the cost for a typical month of medication in the United States is 50 to 100 USD.[6]
References
|
|---|
| Receptor (ligands) | | DP (D2) | | |
|---|
| |
- Antagonists: ADC-3680
- AZD-1981
- Bay U3405
- Fevipiprant
- MK-1029
- MK-7246
- OC-459
- OC000459
- QAV-680
- Ramatroban
- Setipiprant
- TM30089
- Vidupiprant
|
|---|
|
|---|
| | EP (E2) | |
- Antagonists: AH-6809
- ONO-8130
- SC-19220
- SC-51089
- SC-51322
|
|---|
| |
- Antagonists: AH-6809
- PF-04418948
- TG 4-155
|
|---|
| | |
|---|
| |
- Antagonists: GW-627368
- L-161982
- ONO-AE3-208
|
|---|
| Unsorted | |
|---|
|
|---|
| | FP (F2α) | |
|---|
| | IP (I2) | |
|---|
| | TP (TXA2) | |
|---|
| | Unsorted |
- Arbaprostil
- Ataprost
- Ciprostene
- Clinprost
- Cobiprostone
- Delprostenate
- Deprostil
- Dimoxaprost
- Doxaprost
- Ecraprost
- Eganoprost
- Enisoprost
- Eptaloprost
- Esuberaprost
- Etiproston
- Fenprostalene
- Flunoprost
- Froxiprost
- Lanproston
- Limaprost
- Luprostiol
- Meteneprost
- Mexiprostil
- Naxaprostene
- Nileprost
- Nocloprost
- Ornoprostil
- Oxoprostol
- Penprostene
- Pimilprost
- Piriprost
- Posaraprost
- Prostalene
- Rioprostil
- Rivenprost
- Rosaprostol
- Spiriprostil
- Tiaprost
- Tilsuprost
- Tiprostanide
- Trimoprostil
- Viprostol
|
|---|
|
|---|
| Enzyme (inhibitors) | |
|---|
| | Others | |
|---|
| See also: Leukotrienergics |
|